EU規制枠組みにおける持続可能な医薬品包装
Sustainable pharmaceutical packaging under the European Union regulatory framework (原題)
Ivana Mitrevska, Dino Karpicarov, Sonja Burcevska, Elizabeta Karadžinska, Olivera Paneva
🤖 gxceed AI 要約
日本語
本レビューは、EUの包装・包装廃棄物規則（PPWR）とライフサイクル評価（LCA）に基づき、医薬品包装の持続可能性を検討する。材料選択は機能単位やシステム境界に依存し、単一材料の優位性は一般化できないと指摘。PPWRは循環性要件を課すが、医薬品特例やデジタル製品パスポートの非必須性を明示し、製品別のベネフィット・リスク評価を提唱する。
English
This integrative review examines sustainable pharmaceutical packaging under the EU PPWR, emphasizing that LCA outcomes depend on functional unit and system boundaries, so no single material is universally superior. It highlights trade-offs of various materials and notes PPWR's pharmaceutical derogations and non-mandatory Digital Product Passport, advocating a product-specific benefit-risk approach.
Unofficial AI-generated summary based on the public title and abstract. Not an official translation.
📝 gxceed 編集解説 — Why this matters
日本のGX文脈において
日本では医薬品包装の持続可能性はまだ規制主導ではないが、欧州向け輸出企業はPPWR対応が必須。また、SSBJ開示でScope3排出量算定が求められる中、包装材のLCAデータ整備は日本企業にも示唆を与える。
In the global GX context
The paper provides a timely synthesis of EU PPWR implications for pharmaceutical packaging, relevant for global companies navigating circularity requirements and LCA-based claims. It underscores the need for harmonized methodologies and cautions against oversimplified environmental marketing, aligning with ISSB and CSRD expectations for robust sustainability disclosures.
👥 読者別の含意
🔬研究者:LCAの方法論的注意点と医薬品包装の材料比較に関する統合的知見を得られる。
🏢実務担当者:EU市場向け包装設計やPPWR対応、Scope3算定に活用できる。
🏛政策担当者:包装規制と医薬品特例のバランス、LCA基準の調和の重要性を認識できる。
📄 Abstract（原文）
Pharmaceutical packaging must protect medicinal product quality and patient safety while responding to increasing pressure to reduce material use, greenhouse-gas emissions, and packaging waste. This structured integrative review examines how the European Union Packaging and Packaging Waste Regulation, life-cycle evidence, material innovation and digital information systems affect pharmaceutical packaging decisions. Peer-reviewed studies, official legislation, standards and regulatory guidance were critically synthesised, while company data were used only when independently verifiable evidence was unavailable and were explicitly labelled as industry evidence. Published life-cycle assessments show that environmental rankings depend strongly on the functional unit, system boundary, dosage format, secondary packaging, energy mix and end-of-life assumptions; therefore, broad claims that a single material consistently delivers fixed carbon reductions are not scientifically transferable. High-density polyethylene, polypropylene, paper-based structures, polylactic acid and cyclic olefin polymers offer specific opportunities, but each presents trade-offs involving barrier variability, pharmaceutical-grade purity, extractables and leachables, sterilisation, forming performance, recycling infrastructure and regulatory requalification. The PPWR introduces important circularity requirements but also includes pharmaceutical-specific derogations, and it does not automatically impose a Digital Product Passport on every medicinal package. Digital product information and traceability may improve accessibility and data availability, although their environmental benefit, interoperability, validation and cybersecurity requirements need further evidence. Sustainable packaging transitions should therefore follow a product-specific benefit-risk approach in which patient protection and product quality remain non-negotiable, and environmental gains are demonstrated through comparable life-cycle and performance data .
🔗 Provenance — このレコードを発見したソース
- openalex https://doi.org/10.1007/s43621-026-04534-6first seen 2026-09-01 05:15:41
🔔 こうした論文の新着を逃したくない方は キーワードアラート に登録（無料・3キーワードまで）。
gxceed は公開メタデータに基づく研究支援データセットです。要約・翻訳・解説は AI 支援で生成されています。 最終的な解釈・検証は利用者が原典資料に基づいて行うことを前提とします。